Trial Profile

A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation (HSCT) to Reduce the Risk of Infection and Graft vs. Host Disease (GvHD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SER-155 (Primary) ; Vancomycin
Indications Bacteraemia; Graft-versus-host disease; Intra-abdominal infections
Focus Adverse reactions; Pharmacokinetics
Sponsors Seres Therapeutics

02 Dec 2025 According to Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) media release, it has has awarded Seres Therapeutics, Inc. up to US$3.6M in funding to support this trail.
27 May 2025 Results presented in a Seres Therapeutics media release.
29 Apr 2025 According to a Seres Therapeutics media release, data from this trial will be presented at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com